Full history for every metric is available with a Kvantra account
FUREN Group Pharmaceutical Co., Ltd. (600781.SS)
Key financial summary
Financials in CNY| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 5,800 | 6,317 | 5,171 | 2,891 | 1,512 | 1,469 | 1,582 |
| Operating profit | CNY m | -268 | - | |||||
| Net profit | CNY m | 344 | 794 | 150 | -1,331 | -3,250 | -2,846 | -2,798 |
| EPS reported | CNY | -4.54 | -4.45 | |||||
| Operating cashflow per share | CNY | 0.33 | 0.33 | |||||
| Capex per share | CNY | 0.04 | 0.04 | |||||
| FCF per share | CNY | 0.29 | 0.29 | |||||
| Free cash flow | CNY m | 185 | -2,828 | |||||
| Net debt | CNY m | 3,011 | 3,034 | |||||
| Book value equity | CNY m | -2,009 | -2,132 | |||||
| Book value per share | CNY | -3.20 | -3.47 | |||||
| Number of shares | m | 626.99 | 614.49 | |||||
| DPS (TTM paid) | CNY | 0.01 | 0.00 |
Financial summary
Financials in CNY| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.68 | -0.23 | |||||
| P/S LTM | x | 0.93 | 0.31 | |||||
| P/FCF LTM | x | 7.43 | -0.17 | |||||
| EV/EBITDA LTM | x | -2.47 | -18.86 | |||||
| EV/Sales LTM | x | 2.98 | 2.22 | |||||
| Earnings Yield LTM | % | -207.28% | -589.53% | |||||
| FCF Yield | % | 13.46% | -585.54% | |||||
| Quality | ||||||||
| ROE | % | 141.68% | 470.86% | |||||
| ROIC | % | -10.87% | -10.87% | |||||
| Operating margin | % | -18.24% | -18.24% | |||||
| Gross margin | % | 50.29% | 50.29% | |||||
| FCF/Sales | % | 12.59% | 12.59% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -2.90% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | +183.00% | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.38% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -0.18% | -0.20% | |||||
| FCF/Debt | x | 0.06 | -0.88 | |||||
| Net Debt/EBITDA | x | -1.70 | -1.70 | |||||
| EBIT/Net interest | x | -0.39 | -0.39 | |||||
| Net debt/market cap | % | 219.25% | 628.37% | |||||
| Net debt/Equity | x | -1.50 | -1.42 | |||||
| Gross debt/equity | x | -1.60 | -1.50 | |||||
Company overview
FUREN Group Pharmaceutical Co., Ltd. primarily focuses on the development and distribution of medicinal products across China, with key operations located in Henan Province and Shanghai. The company offers a wide array of traditional Chinese medicines, available in various formats such as capsules, tablets, granular formulations, gels, injectable solutions, and oral liquids. Among its notable therapeutic solutions are granular preparations designed for cardiac ailments, alongside encapsulated treatments for managing diabetes and high cholesterol. Furthermore, the company diversifies its business by engaging in warehousing logistics and commercial trading activities. Established in 1996, the firm maintains its headquarters in Shanghai, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
FUREN Group Pharmaceutical Co., Ltd. (600781.SS)
FUREN Group Pharmaceutical Co., Ltd. primarily focuses on the development and distribution of medicinal products across China, with key operations located in Henan Province and Shanghai. The company offers a wide array of traditional Chinese medicines, available in various formats such as capsules, tablets, granular formulations, gels, injectable solutions, and oral liquids. Among its notable therapeutic solutions are granular preparations designed for cardiac ailments, alongside encapsulated treatments for managing diabetes and high cholesterol. Furthermore, the company diversifies its business by engaging in warehousing logistics and commercial trading activities. Established in 1996, the firm maintains its headquarters in Shanghai, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free